Guillain Barre Syndrome (GBS) is found to be a rapidly progressing defence mediated disorder that usually affects the extremities. The most prevalent form seen among the class of GBS is acute inflammatory demyelinating polyneuropathy (AIDP). Cerebrospinal fluid (CSF) evaluation and electrophysiological findings are used mainly to diagnose GBS. The cerebrospinal fluid evaluation shows increased protein levels. Nerve conduction studies show a possible blockage, of conduction. Plasma exchange and intravenous immunoglobulin play a vital part in the treatment of GBS. Supportive therapy includes controlling pain with nonsteroidal anti-inflammatory drugs, carbamazepine, or gabapentin; monitoring for respiratory complications and prevent ing venous thrombosis.GBS is a serious illness and the long-term impact is 3-6 years in GBS patients after the onset of the disease. It will take a long time to recover. In 20-30% of adult patients, chronic illness can be seen, but in children, it is less common. Extreme fatigue is seen in one-third of patients and long term residual problems involve fatigue, pain and psychological disability.